[Cerebrospinal fluid distributions of systemically administered fluorinated pyrimidines].

Abstract

Transfer of systemically administered fluorinated pyrimidines (Tegafur, TAC-278, HCFU and FD-1) to cerebrospinal fluid was studied in 7 patients primary brain tumors. Seven patients had had irradiation and also had V-P shunt operation for hydrocephalus 5-FU concentration in CSF was extremely high in FD-1 and TAC-278 administration, but not in Tegafur and HCFU administration. In addition, Tegafur and HCFU did not reveal any cumulative effects of 5-FU in CSF by continuous prolonged systemic administration. The facts suggest strongly the usefullness of the agents in the treatment of intracranial neoplasms, which have high CSF concentrations. However, intermediate metabolites of 5-FU in CSF are different from those in systemic pathway, and FD-1 and TAC-278 produce CNS toxicities. Therefore, further extensive studies are necessary to utilize these agents for the treatment of intracranial neoplasms.

• Authors: K Sueyoshi, H Majima
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 10 Issue 3 Pg. 818-23 (Mar 1983) ISSN: 0385-0684 [Print] Japan
• PMID: 6309096 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Tegafur
• FD 1
• TAC 278
• carmofur
• Fluorouracil

Topics

• Adult
• Aged
• Antineoplastic Agents (cerebrospinal fluid)
• Brain Neoplasms (cerebrospinal fluid)
• Ependymoma (cerebrospinal fluid)
• Female
• Fluorouracil (analogs & derivatives, cerebrospinal fluid)
• Glioblastoma (cerebrospinal fluid)
• Humans
• Male
• Middle Aged
• Tegafur (analogs & derivatives, cerebrospinal fluid)